Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915201 | 0.90 | LARS1 (0.72) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13899059 | 0.85 | LARS1 (0.56) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13899053 | 0.85 | LARS1 (0.59) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13899061 | 0.85 | LARS1 (0.59) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13898739 | 0.85 | LARS1 (0.59) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13898737 | 0.84 | LARS1 (0.51) | LARS1DRD2ITGB3ITGA2BKCNH2 | |
| SCHEMBL13899035 | 0.84 | LARS1 (0.51) | LARS1DRD2ITGB3ITGA2BKCNH2 | |
| SCHEMBL13898782 | 0.84 | LARS1 (0.55) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13899052 | 0.83 | LARS1 (0.56) | LARS1HRH3HRH2HRH1DRD2 | |
| SCHEMBL13899038 | 0.83 | LARS1 (0.50) | LARS1DRD2ITGB3ITGA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049623-A1 | Imidazolidinone compounds | PKN2, PKN1, EIF2AK2 | LARS1 4511/4885HRH3 1133/4885HRH2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.